

image

1634

PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	08/887,505
	Filing Date	07/02/1997
	First Named Inventor	Kilkuskie, et. al.
	Art Unit	1634
	Examiner Name	D. Johannsen
Total Number of Pages in This Submission	Attorney Docket Number	47508-250US3 HYZ-040 CIP


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	- Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	1. PTO Form 1449 (2 pgs.) 2. 41 Publications	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Ann-Louise Kerner, Ph.D.
Signature	
Date	2/3/04

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Tina M. Dougal
Signature	
Date	2/3/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: C mmissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.




PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kilkuskie, et al.
Serial No.: 08/887,505 Examiner: D. Johannsen
Filed: July 2, 1997 Group Art Unit: 1634
For: OLIGONUCLEOTIDES SPECIFIC FOR HEPATITIS C VIRUS
Atty. Docket No.: 47508.250US3 (HYZ-040 CIP)

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 3rd day of February, 2004.


Tina M. Dougal

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants and their legal representatives hereby make of record on the attached Form PTO-1449 the following publications which are known to them and considered warranting disclosure under 37 C.F.R. §1.56 and 1.97-98.

Copies of the publications listed on the attached Form PTO-1449 are submitted herewith. It is respectfully requested that the Examiner initial and return a copy of the subject Form PTO-1449 with the next Patent Office communication.

The following references were cited in the Examples section of the patent application. Copies of these references not already cited above are not included with this Information Disclosure Statement, but can be furnished upon request.

PUBLICATIONS

Sambrook, et al., (1989) *Molecular Cloning, A Laboratory Manual* (2nd ed.) Col Spring harbor Laboratory Press, pp. 16.30-16.40

Kato, et al, (1990) *Proc. Natl. Acad. Sci. (USA)* Vol. 87, pg. 9524

Lautenberger (1991) *Biotechniques*, Vol. 10, pgs. 778-780

Beaucage (1993) *Meth. Mol. Biol.* Vol. 20, pgs. 33-61

Hogrefe, et al., (1993) *Methods in Molecular Biology*, Vol. 20: "Protocols for Oligonucleotides and Analogs" (Agrawal, ed.) (Human Press Inc., Totowa, NJ)

Hogrefe et al., (1993) *Nucleic Acids Research* Vol. 21, pgs. 2031-2038


Uhlmann, et al., (1990) *Chem. Rev.*, Vol. 90, pgs. 543-584.

The submission of these publications does not constitute a representation by the Applicants that a search has been made or that no better art exists and does not constitute an admission that the listed publications are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed publications, should one or more of the publications be applied against the claims of the present application.

As the Information Disclosure Statement is being filed prior to the mailing date of the first Office Action on the merits, no fee is believed to be due. However, in the event a fee is due, please charge any fee deficiency or credit any overpayment to Deposit Account No. 08-0219.

Respectfully submitted,

Dated: February 3, 2004


Ann-Louise Kerner, Ph.D.
Registration No.33,523
Attorney for Applicants

Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Tel: (617) 526-6192
Fax: (617) 526-5000

1 Subt. For, PTO-1449

Docket Number
47508.250US3
HYZ-040 CIPApplication Number
08/887,505INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Applicant
Kilkuskie, et al.Filing Date
July 2, 1997Group Art Unit
1634

Sheet 1 OF 2

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,071,693	6/2000	Cha, et al	435	6	
	5,866,336	2/2/99	Nazarenko, et al.	435	6	
	5,846,704	12/8/98	Maertens, et al.	435	5	
	5,527,899	6/18/96	Froehler	536	25.3	
	5,424,413	6/13/95	Hogan, et al.	536	24.31	

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 388 232	3/16/90	EP	C12N	15/51		
	0 469 348	7/9/91	EP	C12N	15/51		
	0 518 313	6/11/92	EP	C12N	15/51		
	0 532 258	9/8/92	EP	C12Q	1/70		
	0 554 624	12/24/92	EP	C07K	15/00		
	0 633 321	6/13/94	EP	C12Q	1/70		
	2,104,649	8/23/93	Canada				
	92/19743	5/8/92	WO				
	92/02642	8/12/91	WO				
	94/01550	7/2/93	WO				
	94/08002	9/28/93	WO				
	94/05813	9/10/93	WO				
	95/01442	6/28/94	WO				
	96/35706	5/10/96	WO				
	98/40479	2/12/98	WO				


Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

A1	Bukh, Jens, et al. "Sequence analysis of the 5' noncoding region of hepatitis C virus," 1992, Biochemistry, Vol. 89, pgs. 4942-4946
A2	Fuchs, et al, "Characterization of nucleotide sequences from European hepatitis C virus isolates Gene," 1991, Vol. 103, pgs. 163-169
A3	Hotta, Hak, et al, "Subtype Analysis of Hepatitis C Virus in Indonesia on the Basis of NS5b Region Sequences," 1994, J. Clinical Microbiology, Vol. 32, pgs. 3049-3051
A4	Gura, "Antisense Has Growing Pains," 1995, Science, Vol. 270, pgs. 575-577
A5	James, W., "Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes," 1991, Antiviral Chem. & Chemotherapy, Vol. 2, pgs. 191-214
A6	Martell, Maria, et al., "Dynamic Behavior of Hepatitis C Virus Quasispecies in Patients Undergoing Orthotopic Liver Transplantation, 1994, J. Virology, Vol. 68, pgs. 3425-3436

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



2 Subt. For, PTO-1449				Docket Number 47508.250US3 HYZ-040 CIP		Application Number 08/887,505	
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Kilkuskie, et al.			
				Filing Date July 2, 1997		Group Art Unit 1634	
Sheet	2	OF	2				

A7	Monia, Brett P., et al., "Selective Inhibition of Mutant Ha-ras mRNA Expression by Antisense Oligonucleotides," 1992, J. Bio. Chem., Vol. 267, pgs. 19954-19962
A8	Milligan, John F., et al., "Current Concepts in Antisense Drug Design," 1993, J. Med. Chem., Vol. 36, pgs. 1923-1937
A9	Salunkhe, Manikrao et al., "Control of Folding and Binding of Oligonucleotides by Use of a Nonnucleotide Linker," 1992, J. Am. Chem. Soc., Vol. 114, pgs. 8768-8772
A10	Simmonds, P., et al., "Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity," 1993, J. Gen. Virology, Vol. 74, pgs. 661-667
A11	Stein, A., et al., "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" 1993, Science, Vol. 261, pgs. 1004-1012
A12	Stratagene 1988 Catalog
A13	Stuyver, Lieven, et al., "Typing of Hepatitis C virus isolates and characterization of new subtypes using a line probe assay," 1993, J. Gen. Virology, Vol. 74, pgs. 1093-1102
A14	Stuyver, Lieven, et al., "Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5B regions and identification of five additional subtypes," 1994, Biochemistry, Vol. 91, pgs. 10134-10138
A15	Tseng, B.Y., et al., "Antisense oligonucleotide technology in the development of cancer therapeutics," 1994, Cancer Gene Therapy, Vol. 1 pgs. 65-71
A16	Uhlmann, E., et al., 1990, Antisense Oligonucleotides: A New Therapeutic Principle, Chem. Reviews, Vol. 90, pgs. 543-584
A17	Wakita, et al., 1994, "Specific Inhibition of Hepatitis C Virus Expression by Antisense Oligodeoxynucleotides," J. Bio. Chem. Vol. 269, pgs. 14205-14210
A18	Wang, et al., 1994, "A Conserved Helical Element is Essential for Internal Initiation of Translation of Hepatitis C Virus RNA," J. Virol., Vol. 68, pgs. 7301-7307
A19	Westermann, P. et al., "Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides," 1989, Biomed. Biochim. Acta, Vol. 48, pgs. 85-93
A20	Yoo, Byoung J. et al., 1995, "Transfection of a Differentiated Human Hepatoma Cell Line (Huh7) with In Vitro-Transcribed Hepatitis C Virus (HCV) RNA and Establishment of a Long-Term Culture Persistently Infected with HCV," J. Virol., Vol. 69, pgs. 32-38
A21	Yoo, Byoung, J. et al., 1992, "End-Dependent Translation Initiation of Hepatitis C Viral RNA and the Presence of Putative Positive and Negative Translational Control Elements with the 5' Untranslated Region," J. Virol. Vol. 191, pgs. 889-899

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	